{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:00:55Z","timestamp":1789887655759,"version":"4.0.1"},"reference-count":36,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Type 2 diabetes mellitus (T2DM) is associated with an increased risk of bladder cancer, but the impact of specific antidiabetic drug classes remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We conducted a systematic review and meta-analysis following PRISMA guidelines. PubMed\/MEDLINE, Embase, Scopus and CENTRAL were searched through 2024 for observational studies assessing the association between antidiabetic drug exposure and incident bladder cancer. Adjusted effect estimates (HRs, RRs, ORs) were pooled using random-effects models. Analyses were performed separately for pioglitazone, metformin and sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors. Heterogeneity was assessed using the\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      statistic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Fourteen observational studies including approximately 6.3\u2009million individuals with T2DM were included. Pioglitazone use was not significantly associated with bladder cancer risk (pooled RR\u2009\u2248\u20091.05, 95% CI 0.52\u20132.09), although substantial heterogeneity was observed (\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200999%). Several studies suggested a duration and dose-dependent association, particularly with prolonged exposure. Metformin use was associated with a lower risk of bladder cancer (pooled RR\u2009=\u20090.67, 95% CI 0.46\u20130.98), although substantial heterogeneity was observed. SGLT2 inhibitor use was not associated with an increased risk of bladder cancer (pooled RR\u2009=\u20090.98, 95% CI 0.70\u20131.37), with moderate heterogeneity across studies (\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200963%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>We did not demonstrate a statistically significant association between pioglitazone use and bladder cancer risk. However, several individual studies suggested a possible duration-dependent effect with prolonged exposure. Metformin use was associated with a lower risk of bladder cancer (pooled RR\u2009=\u20090.67, 95% CI 0.46\u20130.98), although substantial heterogeneity was observed. SGLT2 inhibitors appear oncologically safe with respect to bladder cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03915603261486088","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:45:05Z","timestamp":1789710305000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antidiabetic drug exposure and risk of bladder cancer: A systematic review and meta-analysis"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7736-0315","authenticated-orcid":false,"given":"William","family":"Mathez","sequence":"first","affiliation":[{"name":"Department of Urology, CHRU de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Vincentelli","sequence":"additional","affiliation":[{"name":"Department of Urology, CHRU de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iyad","family":"Chaoui","sequence":"additional","affiliation":[{"name":"Department of Urology, CHRU de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bruy\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Urology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bourgi","sequence":"additional","affiliation":[{"name":"Department of Urology, CHRU de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Richters A Aben KKH Kiemeney LALM. The global burden of urinary bladder cancer: an update. World J Urol 2020; 38: 1895\u20131904. https:\/\/doi.org\/10.1007\/s00345-019-02984-4","DOI":"10.1007\/s00345-019-02984-4"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Giovannucci E Harlan DM Archer MC et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674\u20131685. https:\/\/doi.org\/10.3322\/caac.20078","DOI":"10.2337\/dc10-0666"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Larsson SC Orsini N Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49: 2819\u20132823. https:\/\/doi.org\/10.1007\/s00125-006-0468-0","DOI":"10.1007\/s00125-006-0468-0"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Harding JL Shaw JE Peeters A et al. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations detection bias and reverse causation. Diabetes Care 2015; 38: 264\u2013270. https:\/\/doi.org\/10.2337\/dc15-er04a","DOI":"10.2337\/dc14-1996"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Sung H Ferlay J Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Garg SK Maurer H Reed K et al. Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab 2014; 16: 97\u2013110. https:\/\/doi.org\/10.1111\/dom.12124","DOI":"10.1111\/dom.12124"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Ryu TY Park J Scherer PE. Hyperglycemia as a risk factor for cancer progression. Diabetes Metab J 2014; 38: 330\u2013336. https:\/\/doi.org\/10.4093\/dmj.2014.38.5.330","DOI":"10.4093\/dmj.2014.38.5.330"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.4161\/cc.9.8.11512"},{"key":"e_1_3_2_10_2","first-page":"254","article-title":"Basal insulin therapy and cancer risk in type 2 diabetes patients","volume":"35","author":"Dankner R","year":"2012","unstructured":"Dankner R, Chetrit A, Segal P, et al. Basal insulin therapy and cancer risk in type 2 diabetes patients. Diabetes Care 2012; 35: 254\u2013260.","journal-title":"Diabetes Care"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.77"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Johnson JA Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes. Diabetologia 2011; 54: 25\u201331. https:\/\/doi.org\/10.1007\/s00125-010-1933-3","DOI":"10.1007\/s00125-010-1933-3"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Colmers IN Bowker SL Majumdar SR et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012; 184: E675\u2013E683. https:\/\/doi.org\/10.1503\/cmaj.112102","DOI":"10.1503\/cmaj.112102"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Neumann A Weill A Ricordeau P et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012; 55: 1953\u20131962. https:\/\/doi.org\/10.1007\/s00125-012-2538-9","DOI":"10.1007\/s00125-012-2538-9"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Ferwana M Firwana B Hasan R et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med 2013; 30: 1026\u20131032. https:\/\/doi.org\/10.1111\/dme.12144","DOI":"10.1111\/dme.12144"},{"key":"e_1_3_2_16_2","article-title":"Pioglitazone use and risk of bladder cancer: population based cohort study","volume":"352","author":"Tuccori M","year":"2016","unstructured":"Tuccori M, Filion KB, Yin H, et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ 2016; 352: i1541.","journal-title":"BMJ"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Turner RM Kwok CS Chen-Turner C et al. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 2014; 78: 258\u2013273. https:\/\/doi.org\/10.1111\/dme.12144","DOI":"10.1111\/bcp.12306"},{"key":"e_1_3_2_18_2","first-page":"117","article-title":"Carcinogenicity of pioglitazone","volume":"14","author":"International Agency for Research on Cancer","year":"2013","unstructured":"International Agency for Research on Cancer. Carcinogenicity of pioglitazone. Lancet Oncol 2013; 14: 117\u2013118.","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Lewis JD Ferrara A Peng T et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. JAMA 2015; 314: 265\u2013277. https:\/\/doi.org\/10.2337\/dc10-1068","DOI":"10.1001\/jama.2015.13915"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Levin D Bell S Sund R et al. Pioglitazone and bladder cancer risk: a multipopulation pooled cumulative exposure analysis. Diabetologia 2015; 58: 493\u2013504. https:\/\/doi.org\/10.1007\/s00125-014-3456-9","DOI":"10.1007\/s00125-014-3456-9"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Korhonen P Heintjes EM Williams R et al. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using European health registries. Eur J Epidemiol 2016; 31: 187\u2013199. https:\/\/doi.org\/10.1136\/bmj.i3903","DOI":"10.1136\/bmj.i3903"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Pernicova I Korbonits M. Metformin\u2014mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10: 143\u2013156. https:\/\/doi.org\/10.1038\/nrendo.2013.256","DOI":"10.1038\/nrendo.2013.256"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Gandini S Puntoni M Heckman-Stoddard BM et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis. Cancer Prev Res 2014; 7: 867\u2013885. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-13-0424","DOI":"10.1158\/1940-6207.CAPR-13-0424"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Franciosi M Lucisano G Lapice E et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013; 8: e71583. https:\/\/doi.org\/10.1371\/journal.pone.0071583","DOI":"10.1371\/journal.pone.0071583"},{"key":"e_1_3_2_25_2","first-page":"10511","article-title":"Metformin in cancer: new molecular insights","volume":"35","author":"Aldea M","year":"2014","unstructured":"Aldea M, Rousselot P, Gauthier A, et al. Metformin in cancer: new molecular insights. Tumour Biol 2014; 35: 10511\u201310519.","journal-title":"Tumour Biol"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Tseng CH. Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes. Acta Diabetol 2014; 51: 295\u2013303. https:\/\/doi.org\/10.1007\/s00592-014-0562-6","DOI":"10.1007\/s00592-014-0562-6"},{"key":"e_1_3_2_27_2","first-page":"84033","article-title":"Metformin use and bladder cancer risk: a meta-analysis","volume":"7","author":"Zhou X","year":"2016","unstructured":"Zhou X, Zhang P, Wang J, et al. Metformin use and bladder cancer risk: a meta-analysis. Oncotarget 2016; 7: 84033\u201384043.","journal-title":"Oncotarget"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Liu CQ Huang YQ Chen S et al. Metformin use and incidence of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Front Pharmacol 2022; 13: 865988. https:\/\/doi.org\/10.3389\/fphar.2022.865988","DOI":"10.3389\/fphar.2022.865988"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"Mamtani R Pfanzelter N Haynes K et al. Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care 2014; 37: 1910\u20131917. https:\/\/doi.org\/10.2337\/dc13-1489","DOI":"10.2337\/dc13-1489"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Goossens ME Zeegers MP Bazelier MT et al. Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients. Br J Clin Pharmacol 2015; 80: 1464\u20131472. https:\/\/doi.org\/10.1111\/bcp.12740","DOI":"10.1111\/bcp.12740"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","unstructured":"Tsilidis KK Capothanassi D Allen NE et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical practice research datalink. Int J Cancer 2014; 135: 2520\u20132532. https:\/\/doi.org\/10.2337\/dc14-0584","DOI":"10.2337\/dc14-0584"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","unstructured":"Tang H Dai Q Shi W et al. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetologia 2017; 60: 1862\u20131872. https:\/\/doi.org\/10.1007\/s00125-017-4370-8","DOI":"10.1007\/s00125-017-4370-8"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","unstructured":"Abrahami D Tesfaye H Yin H et al. Sodium-glucose cotransporter 2 inhibitors and the short-term risk of bladder cancer: an international multisite cohort study. Diabetes Care 2022; 45: 2907\u20132917. https:\/\/doi.org\/10.2337\/dc22-1174","DOI":"10.2337\/dc22-1174"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Ueda P Svanstr\u00f6m H Hviid A et al. Sodium-glucose cotransporter 2 inhibitors and risk of bladder and renal cancer: Scandinavian cohort study. Diabetes Care 2022; 45: e93\u2013e96. https:\/\/doi.org\/10.2337\/dc21-1917","DOI":"10.2337\/dc21-1917"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","unstructured":"Chung CT Lakhani I Chou OHI et al. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors and cancer risk. Cancer Med 2023; 12: 12299\u201312315. https:\/\/doi.org\/10.1002\/cam4.5927","DOI":"10.1002\/cam4.5927"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","unstructured":"Schmedt N Heintjes EM Morales DR et al. Post-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin. Diabetes Obes Metab 2025; 27: 4401\u20134414. https:\/\/doi.org\/10.1111\/dom.16477","DOI":"10.1111\/dom.16477"},{"key":"e_1_3_2_37_2","first-page":"1839","article-title":"Effects of rosiglitazone on chemically induced bladder carcinogenesis","volume":"123","author":"Lubet RA","year":"2008","unstructured":"Lubet RA, Fischer SM, Steele VE, et al. Effects of rosiglitazone on chemically induced bladder carcinogenesis. Int J Cancer 2008; 123: 1839\u20131843.","journal-title":"Int J Cancer"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261486088","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603261486088","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261486088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:16:17Z","timestamp":1789884977000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603261486088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":36,"alternative-id":["10.1177\/03915603261486088"],"URL":"https:\/\/doi.org\/10.1177\/03915603261486088","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"03915603261486088"}}